Having established their collaboration in the 1980s, this extension represents a long-term commitment to patients, offering the benefits of Decapeptyl in the treatment of metastatic and non-metastatic patients with locally advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty and endocrine-responsive early-stage breast cancer.
Under the renewed agreement, both parties will co-develop novel formulations and explore additional indications for other patient populations with high unmet needs.
“Our continued partnership remains critical to ensure that patients maintain access to Decapeptyl therapy for their various conditions. Furthermore, this renewed agreement represents an opportunity to refine and refocus our collaboration by further exploring our co-development capacity to potentially identify how Decapeptyl can respond to more unmet patient needs,” said Thierry Mauvernay, President & Delegate of the Board Group, Debiopharm
“We are delighted to renew and extend this partnership with Debiopharm. This collaboration has been – and continues to be – a testament to our commitment to patients and our shared passion with strategic partners, “said Ivana Magovčević-Liebisch, Executive Vice-President, Chief Business Officer
Decapeptyl (triptorelin pamoate) is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH), currently available in three sustained-release formulations (1, 3 and 6 months). First registered in France in 1986, triptorelin is currently marketed in more than 80 countries, being the market leader in many territories worldwide.
The alliance between Debiopharm and Ipsen for Decapeptyl has successfully delivered sustained market growth with €372.6 million total sales in 2018, representing 8.1% annual growth.
Source: Company Press Release